DOCSLIB.ORG

G Proteinactivation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
G Proteinactivation US 20200079745A1 INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0079745 A1 Kruegel et al. (43 ) Pub . Date : Mar. 12 , 2020 (54 ) CARBOXYLIC DIARYTHIAZEPINEAMINES Publication Classification AS MIXED MU - AND DELTA -OPIOID (51 ) Int. Ci. RECEPTOR AGONISTS C07D 281/02 ( 2006.01 ) (71 ) Applicants :Andrew Kruegel, New York , NY (US ) ; (52 ) U.S. CI. Dalibor Sames , New York , NY (US ) ; CPC CO7D 281/02 (2013.01 ) ; A61K 45/06 Jonathan A. Javitch , Dobbs Ferry , NY (2013.01 ) (US ) (57 ) ABSTRACT ( 72 ) Inventors : Andrew Kruegel , New York , NY (US ) ; The present invention provides a compound having the Dalibor Sames , New York , NY (US ) ; structure : Jonathan A. Javitch , Dobbs Ferry , NY (US ) Rg Ri (73 ) Assignee : The Trustees of Columbia University in the City of New York , New York , Ro R4 NY (US ) -R5, (21 ) Appl. No .: 16 /493,992 R10 ( 22 ) PCT Filed : Mar. 15 , 2018 R11 N R2 R7 Ro ( 86 ) PCT No .: PCT/ US2018 /022650 R3 $ 371 ( c ) ( 1 ) , or a pharmaceutically acceptable salt or ester thereof , and a (2 ) Date : Sep. 13 , 2019 method of treating a subject afflicted with a pain , a depres sive disorder , a mood disorder, an anxiety disorder , border Related U.S. Application Data line personality disorder, opioid addiction , or opioid with (60 ) Provisional application No. 62 /471,745 , filed on Mar. drawal symptoms by administering the compound to the 15 , 2017 subject . hDOR + GOB - Luc + B1 + y2 - Venus 150 DPDPE 100 GProteinActivation(%) Www Wewe os des . 9c IT Most 12 DI -50 Log (drug ] (M ) Patent Application Publication Mar. 12 , 2020 Sheet 1 of 2 US 2020/0079745 A1 Fig . 1 hDOR + GOB -Luc + B1 + y2 - Venus 150 DPDPE GProteinActivation(%) 50 9c .L DI 3 -2 HH Log ( drug ] ( M ) 50 Patent Application Publication Mar. 12 , 2020 Sheet 2 of 2 US 2020/0079745 A1 Fig . 2 30 TW 25-1 Tianeptine (15 min ) ED50 = 15 mg/ kg Latency(s) 9b ( 15 min ) 20 ED50 = 5.1 mg/ kg 9k ( 15 min ) ED50 1.7 mg/ kg 15 10 0.1 1 10 Baseline Drug (mg /kg ) US 2020/0079745 A1 Mar. 12 , 2020 1 CARBOXYLIC DIARYTHIAZEPINEAMINES [0006 ] Long - acting prescription opioids may also be used AS MIXED MU - AND DELTA -OPIOID as maintenance ( replacement ) therapies in the treatment of RECEPTOR AGONISTS opioid addiction . In this case , a prescription opioid is provided to the patient chronically and under medical super [ 0001 ] This application claims priority of U.S. Provisional vision to substitute for the use of illicit opioids (e.g. heroin ), Application No. 62/ 471,745 , filed Mar. 15 , 2017 , the con thus reducing cravings for , and abuse of, the illicit drug . tents of each of which are hereby incorporated by reference. Opioid maintenance therapy is considered a standard [ 0002 ] Throughout this application , certain publications method of care for opioid addiction and is more successful are referenced in parentheses. Full citations for these pub than behavioral or antagonist interventions (Bart , G. 2012 ) . lications may be found immediately preceding the claims. The disclosures of these publications in their entireties are SUMMARY OF THE INVENTION hereby incorporated by reference into this application in order to describe more fully the state of the art to which this [0007 ] The present invention provides a compound having invention relates . the structure : BACKGROUND OF THE INVENTION Rg [0003 ] The mu opioid receptor (MOR ) has been the major molecular target for treatment of pain for several decades . R9 R4 However, the vast majority of MOR agonists used clinically today are structurally related to or derived from morphine -R5, ( and other poppy alkaloids ). These compounds suffer from R10 many serious problems, including development of tolerance Ril ( increased dosing is required to achieve the same analgesic R7 Ro effects ) , high addiction liability , and other side effects (e.g. R? R3 respiratory depression , nausea , and constipation ) (Williams , J. T. et al. 2013) . Therefore , there is a continuing interest in the development of new pain medications , including new [0008 ] wherein MOR agonists with improved therapeutic profile ( Corbett , [0009 ] Riis1 -H or - (alkyl ) ; A. D. et al. 2006 ) . [ 0010 ] R2 is (Cz - C20 alkyl) -CO2H or — (C3 -C20 alkyl) [ 0004 ] There is also both historical and growing interest in CO2- alkyl) ; the use of MOR agonists as medicaments for depression . [0011 ] R , is - H or -alkyl) ; Prior to the adoption of tricyclic antidepressants and elec [ 0012 ] R4 , R5, R. and R , are each independently —H , troshock therapy as favored treatments for depression , opi Ci, —Br, -F , -1, CN , CF3, — OCF3, - (alkyl ) , oids were among the only options available , with the “ opium -( alkenyl) , - ( alkynyl ), -( aryl ) , -NH2, -NH-( alkyl) , -NH cure " being an accepted treatment modality in the early 20th (alkenyl ) , -NH-( alkynyl) -NH - Caryl) , -NH-(heteroaryl ) , century (Berrocoso , E. et al. 2009 ) . More recently , studies in OH , OAc , O C ( O ) ( alkyl) , O - alkyl) , O - alky both rodents (Besson , A. et al. 1996 ) and humans (Bodkin , laryl) , O-( alkenyl) , O-( alkynyl ) , O - Caryl) , O-( het J. A. et al. 1995 ) have suggested that MOR activation may eroaryl ), S- (alkyl ), —S- ( alkenyl) , —S-( alkynyl) , S lead to antidepressant and / or anxiolytic effects . The antide ( aryl ), S- (heteroaryl ) , -SS ( O ) -( alkyl) ), S ( O )-aryl ), pressant tianeptine has also been reported to act as a full S ( O ) - (heteroaryl ) , SO2- ( alkyl ), -SO2- ( aryl) , or agonist of the MOR (Gassaway , M.M. et al. 2014 ) . On the -SO-(heteroaryl ) ; molecular level , MORs are extensively expressed in the hippocampus and have been shown to exert a variety of [0013 ] Ry, Ry, Rio and Rui are each independently —H , indirectmodulatory effects on glutamatergic neurons in this C1, —Br, —F, —I, CN , CF39 OCF3, - ( alkyl) , brain region ( Xie , C. W. et al . 1997 ; Svoboda, K. R. et al. -aryl ), -( heteroaryl) - (alkenyl ) , - (alkynyl ), -NH2, -NH 1999 ) . Normalization and modulation of glutamate signaling ( alkyl) , NH-( alkenyl) , -NH-( alkynyl ) -NH -Caryl ) , has been strongly associated with the actions of antidepres NH-( heteroaryl ) , OH , -OA , 0_C ( O ) (alkyl ) , sants (Paul , I. A. and Skolnick , P. 2003 ) and indeed , the O - alkyl) , O-( alkenyl ) , O-( alkynyl ) , O - aryl ) , NMDA receptor antagonist ketamine , shows rapid and effi O-( heteroaryl ) , S - alkyl) , -S - alkenyl) , -S - alkynyl) , cacious antidepressant activity in human clinical trials S - aryl) , S-( heteroaryl ) , -S ( O ) - (alkyl ) , -S ( O ) - (aryl ), ( Zarate , C. A. Jr et al. 2006 ) . Further , agonists of the related S ( O )- (heteroaryl ) , SO2- ( alkyl) , -SO2- ( aryl ) , or delta opioid receptor ( DOR ) have been demonstrated to SOZ- (heteroaryl ) ; show robust antidepressant efficacy in animals ( Jutkiewicz , [0014 ] wherein when R , is (C3-6 alkyl) -CO H , then E. M. 2006 ) . one of Rs or Ro is - ( alkynyl) or S-( alkyl ) , or R , and [0005 ] Opioid receptor dysfunction may also be associ Ro are each independently — Cl, —Br, —F, or —I, ated with borderline personality disorder (BPD ) . Patients [0015 ] wherein when R , is – (C3-6 alkyl) -CO2- (alkyl ) , afflicted with BPD exhibit alterations in both basal MOR then one of R , or Rois - ( alkynyl ) , or R , and Roare each binding potential and endogenous opioid responses to nega independently C1, -Br, —F, or —I, tive stimuli (Prossin , A. R. et al. 2010 ) . There is also a high 10016 ] wherein when R , is CH , Rz, R4 , R., Rz, Rg, prevalence of BPD among patients seeking buprenorphine R9, R10 and Ru1 are each H , and R , is Cl, then R2 is treatment for opioid addiction (Sansone , R. A. et al . 2008 ) . other than ( CH2) , CO H , ( CH2) 1.CO2H , CH Accordingly , MOR modulators may be useful medicaments (CH ) ( CH2) CO , H or ( CH2) 2CH (CH3 ) ( CH2) for BPD . 3CO2H , and US 2020/0079745 A1 Mar. 12 , 2020 2 [ 0017 ] wherein when R , is CH3, R3, R4, R6 R7, R8, R9, other than ( CH ) CO2H , (CH2 ) 1.CO H , CH R10 and Rui are each -H , and R , is SCH3, then R2 is other (CH ) (CH ) COZH or - ( CH2) 2CH (CH3 ) (CH2 ) than ( CH2) .CO , H , 3CO , H , and [ 0018 ] or a pharmaceutically acceptable salt or ester [0031 ] wherein when R , is CH3, R3, R4, R6, R7, Rg, thereof . R9, R10 and R11 are each — H , and R , is SCHz, then R2 is other than (CH ).CO , H , BRIEF DESCRIPTION OF THE FIGURES [0032 ] or a pharmaceutically acceptable salt or ester [ 0019 ] FIG . 1 : Compound 9c activates DOR to a lesser thereof. Emax than the control agonist DPDPE . [0033 ] In some embodiments , a compound having the [0020 ] FIG . 2 : Dose - response curves of analgesic activity structure : of tianeptine, 9b and 9k in the hot plate assay. DETAILED DESCRIPTION OF THE Rg R1 INVENTION R9 R4 [0021 ] The present invention provides a compound having the structure : R5, Rió Rg Ri R11 R2 R Ro Ro Lo R4 R3 .R5, [ 0034 ] wherein Rio (0035 ] Ri is -H or - ( alkyl) ; Ru1 [0036 ] R2 is (Co - C20 alkyl) -CO H or (Co - C20 R7 R6 R R3 alkyl) -C02- (alkyl ) ; [0037 ] Rz is -H or - ( alkyl ) ; [ 0038 ] R4, R5, R. and R , are each independently —H , [0022 ] wherein C1, —Br, —F, — I , -CN , –CF3, -OCF3, - (alkyl ) , [0023 ] R1 is H or - ( alkyl) ; - (alkenyl ), - (alkynyl ) , - ( aryl) , —NH2, —NH - alkyl) , [0024 ] R2 is – (Cz - C20 alkyl) -CO , H or —Cz- C20 NH-( alkenyl) , -NH-( alkynyl) -NH - Caryl ) , -NH alkyl) -CO2- (alkyl ) ; ( heteroaryl) , OH , OA , O C ( O ) (alkyl ) , O [0025 ] Rz is –H or - (alkyl ) ; ( alkyl) , O - alkylaryl) , O - alkenyl) , O - alkynyl) , [0026 ] R4, R5, R.
Load more

Recommended publications
  • NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function
    NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function Tommy Weiss Sadan, Ph.D. and Melanie R. Grably, Ph.D. N-Methyl-D-Aspartate Receptor (NMDAR) are ubiquitously expressed along the central nervous system and are instrumental to various physiological processes such as synaptic plasticity and learning. Nevertheless, several mental disabilities including schizophrenia and Alzheimer’s disease are all related to NMDAR dysfunction. Here, we review many aspects of NMDAR function and regulation and describe their involvement in pathophysiological states using Alomone Labs products. Right: Cell surface detection of GluN2B in rat hippocampal neurons. Introduction Mechanism of Action Glutamate is a key neuro-transmitter in the central nervous system and NMDAR activation depends on sequential conformational changes to acts on a variety of cell surface receptors, collectively termed ionotropic relieve the magnesium blockade which is achieved by rapid membrane glutamate receptors (iGluRs)15. The N-Methyl-D-Aspartate receptors (NMDAR) depolarization and binding of both glycine and glutamate ligands6, 21. This in are members of the iGluR superfamily and are pivotal to many physiological turn removes the inhibitory electrostatic forces of magnesium and enables processes such as the formation of long term memory, synaptic plasticity calcium influx and transmission of long lasting signals (i.e. long-term and many other cognitive functions. Therefore, it is not surprising that potentiation), a key mechanism to learning and memory formation10.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • Behavioral Evidence for A-Opioid and 5-HT 2A Receptor Interactions
    European Journal of Pharmacology 474 (2003) 77–83 www.elsevier.com/locate/ejphar Behavioral evidence for A-opioid and 5-HT2A receptor interactions Gerard J. Marek* Department of Psychiatry, Yale School of Medicine, New Haven, CT 06508, USA Received 13 February 2003; received in revised form 3 June 2003; accepted 11 June 2003 Abstract Electrophysiological studies have demonstrated a physiological interaction between 5-HT2A and A-opioid receptors in the medial prefrontal cortex. Furthermore, behavioral studies have found that phenethylamine hallucinogens induce head shakes when directly administered into the medial prefrontal cortex. The receptor(s) by which morphine suppresses head shakes induced by serotonin agonists have not been characterized. We administered A-opioid receptor agonists and antagonists to adult male Sprague–Dawley rats prior to treatment with the phenethylamine hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), which is known to induce head shakes via 5-HT2A receptors. The suppressant action of the moderately selective A-opioid receptor agonist, buprenorphine (ID50f0.005 mg/ kg, i.p.; a A-opioid receptor partial agonist and n-opioid receptor antagonist) was blocked by naloxone and pretreatment with the irreversible A-opioid receptor antagonist clocinnamox. Another A-opioid receptor agonist fentanyl also suppressed DOI-induced head shakes. In contrast, a y-opioid receptor agonist was without effect on DOI-induced head shakes. Thus, activation of A-opioid receptors can suppress head shakes induced by hallucinogenic drugs. D 2003 Elsevier B.V. All rights reserved. Keywords: Phenethylamine; Hallucinogen; 5-HT (5-hydroxytryptamine, serotonin); A-Opioid receptor; Head shake; DOI; 5-HT2A receptor; Buprenorphine; Fentanyl 1.
    [Show full text]
  • Tachykinins and Airway Microvascular Leakage Induced by Hcl Intra-Oesophageal Instillation
    Copyright #ERS Journals Ltd 2002 Eur Respir J 2002; 20: 268–273 European Respiratory Journal DOI: 10.1183/09031936.02.00250902 ISSN 0903-1936 Printed in UK – all rights reserved Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal instillation S. Daoui*,B.D9Agostino#, L. Gallelli#, X. Emonds Alt}, F. Rossi#, C. Advenier* Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal *Dept of Pharmacology, University instillation. S. Daoui, B. D9Agostino, L. Gallelli, X. Emonds Alt, F. Rossi, C. Advenier. Paris V, Paris, France, #Dept of #ERS Journals Ltd 2002. Experimental Medicine, Faculty of ABSTRACT: Gastro-oesophageal reflux is a common clinical disorder associated with Medicine and Surgery, Naples, Italy, }Sanofi Synthelabo Research, Montpel- a variety of respiratory symptoms, including chronic cough and exacerbation of asthma. lier, France. In this study, the potential role of acid-induced tachykinin release was examined in guinea pigs and rabbits, by examining the effects of the tachykinin NK1 and NK3 Correspondence: C. Advenier receptors antagonists (SR 140333 and SR 142801, respectively) (1–10 mg?kg-1)on Universite´ Paris V plasma protein extravasation induced in airways by hydrochloric acid (HCl) infusion in UPRES EA220, Pharmacologie the oesophagus. 45 rue des Saints Pe`res Guinea pigs were anaesthetised with urethane, while rabbits were subject to F-75006 Paris neuroleptoanalgesia with hypnorm. Airway vascular leakage was evaluated by France Fax: 33 142863810 measuring extravasation of Evans blue dye. All animals were pretreated with atropine E-mail: [email protected] (1 mg?kg-1 i.p.), propranolol (1 mg?kg-1 i.p.), phosphoramidon (2.5 mg?kg-1 i.v.) and -1 saline or tachykinin receptor antagonists (1–10 mg?kg i.p.).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • 52Nd Annual Meeting
    ACNP 52nd Annual Meeting Final Program December 8-12, 2013 The Westin Diplomat Resort & Spa Hollywood, Florida President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D. This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology. Dear ACNP Members and Guests, It is a distinct pleasure to welcome you to the 2014 meeting of the American College of Neuropsychopharmacology! This 52nd annual meeting will again provide opportunities for the exercise of the College’s core values: the spirit of Collegiality, promoting in each other the best in science, training and service; participation in Community, pursuing together the goals of understanding the neurobiology of brain diseases and eliminating their burden on individuals and our society; and engaging in Celebration, taking the time to recognize and enjoy the contributions and accomplishments of our members and guests. Under the excellent leadership of Randy Blakely and Pat Levitt, the Program Committee has done a superb job in assembling an outstanding slate of scientific presentations. Based on membership feedback, the meeting schedule has been designed with the goals of achieving an optimal mix of topics and types of sessions, increasing the diversity of participating scientists and creating more time for informal interactions. The presentations will highlight both the breadth of the investigative interests of ACNP membership
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun
    USOO8748131B2 (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun. 10, 2014 (54) CHIMERIC NEUREGULINS AND METHOD in Neuregulin-1/ErbB Signaling. The Journal of Biological Chemis OF MAKING AND USE THEREOF try vol. 285, No. 41, pp. 31388-31398, Oct. 8, 2010.* Veronese et al., PEGylation. Successful approach to drug delivery. (71) Applicant: Morehouse School of Medicine, Drug Discovery Today vol. 10, No. 21 Nov. 2005, 1451-1458.* Atlanta, GA (US) Carraway et al., Neuregulin-2, a new ligand ErbB3/ErbB4-receptor tyrosine kinases. Nature, vol. 387, May 29, 1997, 512-516.* (72) Inventor: Byron D. Ford, Atlanta, GA (US) Higashiyamaet al., ANovel Brain-Derived Member of the Epidermal Growth Factor Family That Interacts with ErbB3 and ErbB4. J. (73) Assignee: Morehouse School of Medicine, Biochem. 122,675-680 (1997).* Atlanta, GA (US) Fischbach et al., “ARIA: A Neuromuscular Junction Neuregulin.” Annual Review of Neuroscience, 1997, pp. 429–458, vol. 20. (*) Notice: Subject to any disclaimer, the term of this Buonanno et al., “Neuregulin and ErbB receptor signaling pathways patent is extended or adjusted under 35 in the nervous system.” Current Opinion in Neurobiology, 2001, pp. U.S.C. 154(b) by 0 days. 287-296, vol. 11. Burden et al., “Neuregulins and Their Receptors: A Versatile Signal Appl. No.: 13/627,555 ing Module in Organogenesis and Oncogenesis. Neuron, 1997, pp. (21) 847-855, vol. 18. Fu et al., “Cdk5 is involved in neuregulin-induced AChR expression (22) Filed: Sep. 26, 2012 at the neuromuscular junction.” Nature Neuroscience, Apr.
    [Show full text]
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid
    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
    [Show full text]
  • Targeting Nitric Oxide and NMDA Receptor-Associated Pathways in Treatment of High Grade Glial Tumors
    Nitric Oxide 79 (2018) 68–83 Contents lists available at ScienceDirect Nitric Oxide journal homepage: www.elsevier.com/locate/yniox Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones T ∗ Meric A. Altinoz , İlhan Elmaci Neuroacademy Group, Department of Neurosurgery, Memorial Hospital, Istanbul, Turkey ARTICLE INFO ABSTRACT Keywords: Glioblastoma multiforme (GBM) is a devastating brain cancer with no curative treatment. Targeting Nitric Oxide Nitric oxide (NO) and glutamatergic pathways may help as adjunctive treatments in GBM. NO at low doses promotes tu- Nitrone morigenesis, while at higher levels (above 300 nM) triggers apoptosis. Gliomas actively secrete high amounts of Nitro-memantine glutamate which activates EGR signaling and mediates degradation of peritumoral tissues via excitotoxic injury. Glial tumor Memantine inhibits NMDA-subtype of glutamate receptors (NMDARs) and induces autophagic death of glioma Glioblastoma cells in vitro and blocks glioma growth in vivo. Nitro-memantines may exert further benefits by limiting NMDAR signaling and by delivery of NO to the areas of excessive NMDAR activity leading NO-accumulation at tumor- icidal levels within gliomas. Due to the duality of NO in tumorigenesis, agents which attenuate NO levels may also act beneficial in treatment of GBM. Nitrone compounds including N-tert-Butyl-α-phenylnitrone (PBN) and its disulfonyl-phenyl derivative, OKN-007 suppress free radical formation in experimental cerebral ischemia. OKN-007 failed to show clinical efficacy in stroke, but trials demonstrated its high biosafety in humans including elderly subjects. PBN inhibits the signaling pathways of NF-κB, inducible nitric oxide synthase (iNOS) and cy- clooxygenase (COX).
    [Show full text]
  • Compositions for Treating Centrally Mediated
    (19) TZZ Z_T (11) EP 2 722 045 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4178 (2006.01) A61K 31/473 (2006.01) 06.07.2016 Bulletin 2016/27 A61K 31/496 (2006.01) A61K 31/573 (2006.01) A61K 45/06 (2006.01) A61K 9/00 (2006.01) (2006.01) (2006.01) (21) Application number: 14151683.1 A61K 9/20 A61K 9/48 A61P 1/08 (2006.01) (22) Date of filing: 18.11.2010 (54) Compositions for treating centrally mediated nausea and vomiting Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen Compositions pour traiter les nausées et vomissements à médiation centrale (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A1-2008/049552 WO-A2-2007/096763 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • REDDY G KESAVA ET AL: "Novel neurokinin-1 antagonists as antiemetics for the treatment of (30) Priority: 18.11.2009 US 262470 P chemotherapy-induced emesis.", SUPPORTIVE 14.09.2010 US 382709 P CANCER THERAPY 1 APR 2006 LNKD- PUBMED:18632487, vol. 3, no. 3, 1 April 2006 (43) Date of publication of application: (2006-04-01), pages140-142, XP002626039, ISSN: 23.04.2014 Bulletin 2014/17 1543-2912 • DIEMUNSCH P ET AL: "Neurokinin-1 receptor (62) Document number(s) of the earlier application(s) in antagonists in the prevention of postoperative accordance with Art.
    [Show full text]
  • ( 12 ) United States Patent
    US009974742B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 974 , 742 B2 Ottoboni et al. (45 ) Date of Patent: * May 22, 2018 ( 54 ) EMULSION FORMULATIONS OF AN NK - 1 2013 /0236501 A1 * 9 /2013 Booth . .. .. .. A61K 9 /0019 424 / 400 RECEPTOR ANTAGONIST AND USES 2013 /0317016 AL 11 /2013 Hingorani et al. THEREOF 2016 / 0024092 Al 1 / 2016 Wan et al. 2016 / 0082013 Al 3 / 2016 Ottoboni et al . @(71 ) Applicant : Heron Therapeutics , Inc. , Redwood 2016 /0206622 A1 3 / 2016 Ottoboni et al . City , CA (US ) 2017 / 0112847 AL 4 /2017 Ottoboni et al. @(72 ) Inventors : Thomas B . Ottoboni, Belmont, CA (US ) ; Han Han , Mountain View , CA FOREIGN PATENT DOCUMENTS (US ) CN 102379 * 3 / 2012 CN 102379845 A 3 / 2012 @(73 ) Assignee : Heron Therapeutics, Inc. , San Diego , WO WO 2005 /016308 AL 2 / 2005 WO WO 2009 / 124756 AL 10 / 2009 CA (US ) WO WO 2011 / 158053 AL 12 / 2011 WO WO 2013 / 177501 A2 11 / 2013 @( * ) Notice : Subject to any disclaimer , the term of this WO WO 2014 /0209962 AL 12 /2014 patent is extended or adjusted under 35 WO WO 2014 /005606 AL 3 / 2016 U . S . C . 154 ( b ) by 0 days . days . WO WO 2016 /044784 Al 3 / 2016 This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS (21 ) Appl. No. : 15 /012 , 532 Cassileth et al. in Arch . Intern Med . 1983 ; 143 ( 7 ) : 1347 - 1349 ( Abstract ) . * Dexamethasone Hydrogen Phosphate at web .archive . org/ web / ( 22 ) Filed : Feb . 1 , 2016 20141224130045 /http :/ /www . drugs . com / pro / dexamethasone -so dium -phosphate .html ( retrieved on the internet Mar.
    [Show full text]